Patients who were naive to daratumumab experienced an overall response rate of 91.7%; median progression-free survival in this cohort was not reached.
Continued approval of Xpovio for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
The FDA has expanded the approval of Darzalex (daratumumab; Janssen Biotech) to include use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Median overall survival was 3.6 years for patients who received upfront therapy and 4.2 years for patients who did not.
The rate of infusion reactions was substantially lower in patients receiving SC compared with intravenous daratumumab.
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Lenalidomide reduced the risk of disease progression in patients with intermediate- or high-risk smoldering multiple myeloma, but discontinuation rates were high.
Patients receiving daratumumab demonstrated a statistically significant decline in pain symptoms that was sustained over time.
When added to bortezomib, thalidomide, and dexamethasone, daratumumab was associated with higher rates of measurable disease negativity.
Patients with both high and standard cytogenetic risk who received daratumumab experienced increased PFS.
Carfilzomib administered once weekly demonstrated benefit in progress-free survival independent of patient frailty.
Researchers developed a new model for risk stratification in patients with SMM based on updated criteria.
Median progression-free survival was 22.3 months in patients receiving carfilzomib and 22.1 months in patients receiving bortezomib.
Identifying patients with smoldering myeloma at high risk for disease progression may allow for implementation of better treatment strategies.
Busulfan plus melphalan may be a viable pretreatment conditioning regimen for patients undergoing autologous hematopoietic stem cell transplantation.
Proteasome inhibitors and immunomodulatory drugs have demonstrated improvements in survival and response in patients with multiple myeloma.
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Translocations of IgL occurred in approximately 10% of patients with newly diagnosed multiple myeloma.
Pomalidomide, cyclophosphamide, and dexamethasone triplet therapy for relapsed/refractory multiple myeloma had an overall response rate of 76%.
This action does not impact currently approved indications for venetoclax.
Researchers were able to gain a better understanding of the clonal genetic landscape of relapsed multiple myeloma following autologous stem cell transplantation.
The Food and Drug Administration (FDA) has approved a split-dosing regimen for Darzalex (daratumumab; Janssen), which provides clinicians the option of splitting the first infusion of daratumumab over 2 consecutive days.
Advances in genetic and molecular assessment strategies have led to improved outcomes for patients with multiple myeloma.
Each of 3 reduced intensity conditioning regimens yielded similar clinical outcomes in patients with multiple myeloma undergoing allogeneic stem cell transplant.
Though imaging provides a powerful tool for diagnosis and treatment of multiple myeloma, choosing the appropriate technique depends on many factors.
Depth of response corresponded to overall survival and time to next treatment in real-world patients with relapsed/refractory multiple myeloma.
Researchers emphasized the need for novel condition regimens and a standardized post-transplantation maintenance approach.
Patients who did not have immune dysregulation had higher overall survival compared with patients who had immune dysregulation.
The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.
Stringent CR criteria may not predict clinical outcomes for patients with MM.
Results of a comparison study, presented at ASH 2018, found that salvage HDCT followed by ASCT in patients with relapsed MM did not lead to significant difference in PFS or OS compared with continuous novel agent-based treatment.
Patients who received elotuzumab plus pomalidomide and dexamethasone demonstrated longer progression-free survival.
Therapeutic options for myeloma bone disease include bisphosphonates, immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies.
Bortezomib-based induction therapy is the current standard of care for patients with multiple myeloma, but thalidomide is a promising contender.
Intermediate-dose cytarabine has been demonstrated to have high efficacy as a chemomobilization agent.
Approval was based on results from ELOQUENT-3, a Phase 2, open-label trial (N=117) involving patients with relapsed or refractory multiple myeloma.
Partial remission or better was observed in 85% of evaluable patients who received pomalidomide, cyclophosphamide, and dexamethasone.
PET-CT scans can reveal abnormalities such as bony lesions and extramedullary disease in patients with multiple myeloma.
Screening first-degree relatives of patients with MM may be a viable prevention strategy.
STRO-001 targets CD74, which is a protein highly expressed in B-cell malignancies like multiple myeloma.
First-degree relatives of patients with multiple myeloma were found to be at a higher risk of developing monoclonal gammopathy of undetermined significance.
An updated network meta-analysis found that a triplet regimen consisting of lenalidomide and dexamethasone plus an immunotherapeutic agent had better efficacy in terms of NRR, TTP, PFS, and OS than other regimens.
Previous studies showed that elotuzumab plus lenalidomide and dexamethasone improved progression-free survival and response rates, but its impact on patient-reported outcomes is unknown.
Researchers found that clarithromycin plus bortezomib does not confer any additional efficacy and is a toxic in patients with multiple myeloma.
Researchers investigated cancer-related fatigue in 16 patients with multiple myeloma who were treated with bortezomib, lenalidomide, or thalidomide.
Abdominal adiposity was determined to be a better predictor of risk for hematological malignancies compared with BMI.
There is paucity of comparative and efficacy information on novel agents used as frontline induction therapies in multiple myeloma.
Levels of hemoglobin, combined with ESR, PV, and calcium values, were determined to be the blood parameters with the most diagnostic value in multiple myeloma.
High-dose melphalan is a frequently before ASCT in MM, but is associated with high rates of adverse events.
Reinforcing the immune system with a the PVX-410 vaccine may prevent or slow progression to multiple myeloma.
Drug coverage status influenced the treatments that were selected for Medicare beneficiaries with myeloma and, consequently, their overall survival.